Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Research Study Evaluating the Safety, Tolerability and Biological Effects of the Chimeric Anti-CD40 Monoclonal Antibody Chi Lob 7/4 Given Intravenously, Weekly for Four Weeks in the Treatment of Patients With Advanced Malignancies Refractory to Conventional Anti-cancer Treatment.
Conditions
Interventions
Chi Lob 7/4 (A chimeric monoclonal antibody)
Locations
2
United Kingdom
Cancer Research UK Institute for Cancer Studies, University of Birmingham
Edgbaston, Birmingham, United Kingdom
Cancer Research UK Medical Oncology Unit, Southampton General Hospital
Tremona Road,, Southampton, United Kingdom
Start Date
July 1, 2007
Primary Completion Date
October 1, 2014
Completion Date
October 1, 2014
Last Updated
December 2, 2014
NCT04235764
NCT07388563
NCT04704661
NCT03375307
NCT07213804
NCT04550494
Lead Sponsor
Cancer Research UK
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions